Hasil Pencarian - Shunsuke Teraoka, MD

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study

    Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study oleh Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Takao Inoue, MD, Satoshi Oizumi, MD, PhD, Shigeyuki Toyoizumi, MS, Masakazu Matsumura, MS, Rossella Messina, PharmD, PhD, Terufumi Kato, MD

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN

    First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN oleh Hidetoshi Hayashi, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Toru Kumagai, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Satoshi Oizumi, MD, PhD, Masakazu Matsumura, MS, Masayuki Okura, PhD, Gerson Peltz, MD, MPH, Terufumi Kato, MD

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study

    Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study oleh Hiroaki Akamatsu, MD, PhD, Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Daichi Fujimoto, MD, Atsushi Hayata, MD, PhD, Koji Haratani, MD, PhD, Yuichi Ozawa, MD, PhD, Takeshi Yoshida, MD, PhD, Tsutomu Iwasa, MD, PhD, Toshio Shimokawa, MD, Keisuke Tomii, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

    Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC oleh Qing Zhou, MD, PhD, Ross A. Soo, MBBS, PhD, Gee-Chen Chang, MD, PhD, Chao-Hua Chiu, MD, Hidetoshi Hayashi, MD, PhD, Sang-We Kim, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Jianying Zhou, MD, Victor Ho-Fun Lee, MD, Dong-Wan Kim, MD, PhD, Baohui Han, MD, PhD, James Chung Man Ho, MD, FRCP, Chia-Chi Lin, MD, PhD, Shun Lu, MD, Anna Polli, BS, Anna Maria Calella, PhD, Jean-François Martini, PhD, Chew Hooi Wong, PhD, Tony Mok, MD, Hye Ryun Kim, MD, PhD, Yi-Long Wu, MD

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

    Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations oleh Kiichiro Ninomiya, MD, PhD, Shunsuke Teraoka, MD, Yoshitaka Zenke, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Yukiko Nakamura, MD, Yusuke Okuma, MD, PhD, Akihiro Tamiya, MD, Kaname Nosaki, MD, Masahiro Morise, MD, PhD, Keiju Aokage, MD, Yuko Oya, MD, Toshiyuki Kozuki, MD, PhD, Tomohiro Sakamoto, MD, PhD, Kentaro Tanaka, MD, PhD, Hisashi Tanaka, MD, PhD, Junko Tanizaki, MD, PhD, Satoru Miura, MD, PhD, Hideaki Mizutani, MD, Eisaku Miyauchi, MD, PhD, Ou Yamaguchi, MD, PhD, Noriyuki Ebi, MD, Yasushi Goto, MD, PhD, Takaaki Sasaki, MD, PhD, Haruko Daga, MD, PhD, Satoshi Morita, PhD, Takeharu Yamanaka, PhD, Shinsuke Amano, BCom, Kazuo Hasegawa, BFA, Chiyo K. Imamura, PhD, Kenichi Suzuki, PhD, Kazuko Nakajima, PhD, Hitomi Nishimoto, MN, Satoshi Oizumi, MD, PhD, Toyoaki Hida, MD, PhD, Katsuyuki Hotta, MD, PHD, MPH, Yuichi Takiguchi, MD, PhD

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: